Seres Therapeutics Reports Officer Changes and Disclosure
Ticker: MCRB · Form: 8-K · Filed: Feb 26, 2024 · CIK: 1609809
| Field | Detail |
|---|---|
| Company | Seres Therapeutics, Inc. (MCRB) |
| Form Type | 8-K |
| Filed Date | Feb 26, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.001, $480,000, $80,000, $500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: officer-changes, compensatory-arrangements, regulation-fd
TL;DR
**Seres Therapeutics just filed an 8-K about changes in officers and their pay, so keep an eye out for details!**
AI Summary
Seres Therapeutics, Inc. filed an 8-K on February 26, 2024, reporting an event that occurred on February 24, 2024. The filing pertains to Item 5.02, "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers," and Item 7.01, "Regulation FD Disclosure," and Item 9.01, "Financial Statements and Exhibits." The company's business address is 101 Cambridgepark Drive, Cambridge, MA 02140.
Why It Matters
Changes in executive leadership or compensatory arrangements can signal strategic shifts or financial health, impacting investor confidence and future company direction.
Risk Assessment
Risk Level: medium — Changes in executive compensation or officer roles can introduce uncertainty, but without specific details on the changes, the immediate impact is unclear.
Key Players & Entities
- Seres Therapeutics, Inc. (company) — Registrant
- February 24, 2024 (date) — Date of earliest event reported
- February 26, 2024 (date) — Filing date
- Delaware (company) — State of incorporation
- 001-37465 (dollar_amount) — Commission File Number
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 24, 2024.
What items are covered in this 8-K filing?
This 8-K filing covers Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits).
What is the full name of the registrant?
The exact name of the registrant as specified in its charter is SERES THERAPEUTICS, INC.
Where is Seres Therapeutics, Inc.'s principal executive office located?
Seres Therapeutics, Inc.'s principal executive office is located at 101 Cambridgepark Drive, Cambridge, MA 02140.
What is the state of incorporation for Seres Therapeutics, Inc.?
Seres Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 1,948 words · 8 min read · ~6 pages · Grade level 11.9 · Accepted 2024-02-26 07:06:02
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share MCRB The Nasdaq Stock Mar
- $480,000 — eceive an initial annual base salary of $480,000 and a one-time cash sign-on bonus of $8
- $80,000 — 00 and a one-time cash sign-on bonus of $80,000. Ms. Thorell will also be eligible to r
- $500 — irement in exchange for a hourly fee of $500. Mr. Arkowitz is expected to provide up
Filing Documents
- d784620d8k.htm (8-K) — 36KB
- d784620dex991.htm (EX-99.1) — 8KB
- g784620dsp10.jpg (GRAPHIC) — 10KB
- 0001193125-24-045328.txt ( ) — 181KB
- mcrb-20240224.xsd (EX-101.SCH) — 3KB
- mcrb-20240224_lab.xml (EX-101.LAB) — 17KB
- mcrb-20240224_pre.xml (EX-101.PRE) — 11KB
- d784620d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including statements about the executive transitions and related agreements described herein. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to the factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the SEC, on November 2, 2023, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report on Form 8-K. Any such forward-looking statements represent management's estimates as of the date of this Current Report on Form 8-K. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Current Report on Form 8-K. Item9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following Exhibit 99.1 relates to Item 7.01 and shall be deemed to be furnished, and not filed: Exhibit Description 99.1 Press Release dated February 26, 2024. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 26, 2024 SERES THERAPEUTICS, INC. By: /s/ Thomas J. DesRosier Name: Thomas J. DesRosier Title: Chief Legal Officer and Executive Vice President